These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32932224)

  • 1. The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.
    Mastboom MJL; Lips W; van Langevelde K; Mifsud M; Ng C; McCarthy CL; Athanasou NA; Gibbons CLMH; van de Sande MAJ
    Surg Oncol; 2020 Dec; 35():261-267. PubMed ID: 32932224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.
    Verspoor FGM; Mastboom MJL; Hannink G; Maki RG; Wagner A; Bompas E; Desai J; Italiano A; Seddon BM; van der Graaf WTA; Blay JY; Brahmi M; Eberst L; Stacchiotti S; Mir O; van de Sande MAJ; Gelderblom H; Cassier PA
    Sci Rep; 2019 Oct; 9(1):14551. PubMed ID: 31601938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.
    Mastboom MJL; Palmerini E; Verspoor FGM; Rueten-Budde AJ; Stacchiotti S; Staals EL; Schaap GR; Jutte PC; Aston W; Gelderblom H; Leithner A; Dammerer D; Takeuchi A; Thio Q; Niu X; Wunder JS; ; van de Sande MAJ
    Lancet Oncol; 2019 Jun; 20(6):877-886. PubMed ID: 31029509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
    Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; van der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY
    Cancer; 2012 Mar; 118(6):1649-55. PubMed ID: 21823110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severity classification of Tenosynovial Giant Cell Tumours on MR imaging.
    Mastboom MJL; Verspoor FGM; Hanff DF; Gademan MGJ; Dijkstra PDS; Schreuder HWB; Bloem JL; van der Wal RJP; van de Sande MAJ
    Surg Oncol; 2018 Sep; 27(3):544-550. PubMed ID: 30217317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenosynovial Giant Cell Tumors in Children: A Similar Entity Compared With Adults.
    Mastboom MJL; Verspoor FGM; Uittenbogaard D; Schaap GR; Jutte PC; Schreuder HWB; van de Sande MAJ
    Clin Orthop Relat Res; 2018 Sep; 476(9):1803-1812. PubMed ID: 29494352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.
    Takeuchi A; Nomura A; Yamamoto N; Hayashi K; Igarashi K; Tandai S; Kawai A; Matsumine A; Miwa S; Nishida Y; Nakamura T; Terauchi R; Hoshi M; Kunisada T; Endo M; Yoshimura K; Murayama T; Tsuchiya H
    BMC Musculoskelet Disord; 2019 Feb; 20(1):68. PubMed ID: 30738433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
    Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
    Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of tenosynovial giant cell tumour of the foot and ankle.
    Spierenburg G; Lancaster ST; van der Heijden L; Mastboom MJL; Gelderblom H; Pratap S; van de Sande MAJ; Gibbons CLMH
    Bone Joint J; 2021 Apr; 103-B(4):788-794. PubMed ID: 33789469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.
    Spierenburg G; Grimison P; Chevreau C; Stacchiotti S; Piperno-Neumann S; Le Cesne A; Ferraresi V; Italiano A; Duffaud F; Penel N; Metzger S; Chabaud S; van der Heijden L; Pérol D; van de Sande MAJ; Blay JY; Gelderblom H
    Eur J Cancer; 2022 Sep; 173():219-228. PubMed ID: 35932628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging features for diffuse-type tenosynovial giant cell tumor of the temporomandibular joint: A case report.
    Hu Y; Kuang B; Chen Y; Shu J
    Medicine (Baltimore); 2017 Jun; 96(26):e7383. PubMed ID: 28658169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 16. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.
    Bernthal NM; Spierenburg G; Healey JH; Palmerini E; Bauer S; ; Gelderblom H; Staals EL; Lopez-Bastida J; Fronk EM; Ye X; Laeis P; van de Sande MAJ
    Orphanet J Rare Dis; 2021 Apr; 16(1):191. PubMed ID: 33926503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of arthroscopic excision based on the distribution of the tenosynovial giant cell tumor around knee joint.
    Yoo HJ; Nam HS; Park SB; Lee YS
    Knee; 2023 Mar; 41():360-372. PubMed ID: 36848705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function.
    Verspoor FGM; Mastboom MJL; Hannink G; van der Graaf WTA; van de Sande MAJ; Schreuder HWB
    Bone Joint J; 2019 Mar; 101-B(3):272-280. PubMed ID: 30813787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
    Tap WD; Gelderblom H; Palmerini E; Desai J; Bauer S; Blay JY; Alcindor T; Ganjoo K; Martín-Broto J; Ryan CW; Thomas DM; Peterfy C; Healey JH; van de Sande M; Gelhorn HL; Shuster DE; Wang Q; Yver A; Hsu HH; Lin PS; Tong-Starksen S; Stacchiotti S; Wagner AJ;
    Lancet; 2019 Aug; 394(10197):478-487. PubMed ID: 31229240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.